USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
IMMUNOMEDICS, INC.
Address:
300 The American Road
Morris Plains, NJ 07950-
Phone:
N/A
URL:
N/A
EIN:
161100936
DUNS:
115350605
Number of Employees:
N/A
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $4,518,741.00 36
SBIR Phase II $10,185,987.00 10
STTR Phase I $191,143.00 1

Award List:

THE OBJECT OF THIS PROJECT IS TO PRODUCE A KIT THAT UTILIZES ANTI-CSAP MONOCLONAL ANTIBODIES (MABS) FOR CLINICAL RADIOIMMUNODETECTION (RAID) OF COLORECTAL AND PANCREATIC CANCERS.

Award Year / Program / Phase:
1985 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
HHS
Principal Investigator:
Dan shochat , PRINCIPAL INVESTIGATOR
Abstract:
The object of this project is to produce a kit that utilizes anti-csap monoclonal antibodies (mabs) for clinical radioimmunodetection (raid) of colorectal and pancreatic cancers. phase i will be devoted to selection of hybridomas with specificity to csap, and mabs that are suitable for imaging. it… More

THIS PROJECT WILL EVALUATE ANTIBODY-MEDIATED, POLYMER-BOUND YTTRIUM-90 AS A CANCER THERAPY AGENT.

Award Year / Program / Phase:
1985 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
HHS
Principal Investigator:
Gary griffiths , PRINCIPAL INVESTIGATOR
Abstract:
This project will evaluate antibody-mediated, polymer-bound yttrium-90 as a cancer therapy agent. antibodies will be coupled through one covalent bond to a small polylysine unit. the latter will carry, via a bifunctional coupling agent, molecules of the trivalent metal chelating siderophore,… More

THIS PROJECT IS CONCERNED WITH THE DEVELOPMENT OF NONENZYMATIC REAGENTS FOR IMMUNOHISTOCHEMISTRY, WITH EMPHASIS ON ADAPTING THE NEW TECHNOLOGY TO THE EXPANDING FIELD OF IMMUNOHISTOCHEMICAL DIAGNOSIS OF CANCER.

Award Year / Program / Phase:
1985 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
HHS
Principal Investigator:
Dan shochat , PRINCIPAL INVESTIGATOR
Abstract:
This project is concerned with the development of nonenzymatic reagents for immunohistochemistry, with emphasis on adapting the new technology to the expanding field of immunohistochemical diagnosis of cancer. phase i involves the development of the first family of reagents, namely, phenazine… More

MONOCLONAL ANTIBODY FOR THERAPY AND DIAGNOSIS

Award Year / Program / Phase:
1985 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
HHS
Principal Investigator:
Boby M. Sundoro , Principal Investigator
Abstract:
N/a

THE AIM OF THIS PHASE I PROJECT IS TO DEVELOP NOVEL ANTIBODYCONJUGATES FOR USE IN THE RADIOIMMUNODETECTION OF TUMORS.

Award Year / Program / Phase:
1986 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
HHS
Principal Investigator:
Gary l griffiths , PRINCIPAL INVESTIGATOR
Abstract:
The aim of this phase i project is to develop novel antibodyconjugates for use in the radioimmunodetection of tumors. in response to the problems associated with the antibody- dtpa-radiometal imaging methodologies with regard to liver deposition of the metal, a number of more specific chelatorswill… More

MONOCLONAL ANTIBODY FOR THERAPY AND DIAGNOSIS

Award Year / Program / Phase:
1988 / SBIR / Phase II
Award Amount:
$500,000.00
Agency:
HHS
Principal Investigator:
Boby M. Sundoro , Principal Investigator
Abstract:
The continuing development and evaluation of new radiochelation agents are of utmost importance in tumor imaging with anticancer antibodies. while dtpa-labeled in-111-radioim-munopharmaceuticals are widely used as tumor imaging agents, their high liver background is a disadvantage in providing a… More

THE PRODUCTION OF 188 RE-LABELED MONOCLONAL ANTIBODIES

Award Year / Program / Phase:
1992 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
HHS
Principal Investigator:
Gary L Griffiths
Abstract:
The aim of this project is to ultimately develop novel therapeutic agents for the treatment of cancer. the agents are based on the use of radiolabeled monoclonal antibody bearing the isotope, rhenium-188. this isotope is a generator produced item which could be used in any nuclear pharmacy in a… More

Carcinoembryonal Antigen Idiotype Vaccine

Award Year / Program / Phase:
1993 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
HHS
Principal Investigator:
Hans J. Hansen
Abstract:
Cancer patients are usually tolerant to the antigens expressed on tumor cells. Triggering an active immune response by the patients to tumor-associated antigens represents one of the most promising prospects in cancer therapy. In this project, we will perform a preclinical study of the anti-idiotype… More

Humanized Antibody (MA5) for Breast Cancer Treatment

Award Year / Program / Phase:
1993 / SBIR / Phase I
Award Amount:
$49,999.00
Agency:
HHS
Principal Investigator:
Shui-On Leung
Abstract:
The objective is to re-engineer a murine monoclonal antibody (MAb) by recombinant DNA technologies in order to more effectively treat breast carcinoma patients by the in vivo administration of radioimmunoconjugates. Phase I is focused on the generation of a "humanized" MAb (MA5), which reacts with a… More

TC-99M-F(AB)2 Instant Kits for Radioimmunoscintigraphy

Award Year / Program / Phase:
1993 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
HHS
Principal Investigator:
Gary L. Griffiths
Abstract:
The goal is to develop the optimum clinical agent for radioimmunoscintigraphy. The optimum nuclide is undoubtedly technetium- 99m. Comparing IgG-SH, F(ab')2-SH and Fab'-SH, it is expected that a F(ab')2-SH fragment will have fast enough clearance from circulation to permit earlier imaging than a… More

Engineering a Unique Conjugation Site on AB Light Chain

Award Year / Program / Phase:
1994 / SBIR / Phase I
Award Amount:
$75,000.00
Agency:
HHS
Principal Investigator:
Shui-On Leung
Abstract:
Our objective is to establish that the naturally occurring asparagine- (Asn)- glycosylation sitefound in the light chain variable domain (VK) of a monoclonal antibody (MAb); LL2, is a potential site forthe universal conjugation of cytotoxic agents (e.g., doxorubicin) for cancer therapy. Phase I is… More

Practical RE 186 Labeled Products for Radioimmunotherapy

Award Year / Program / Phase:
1994 / SBIR / Phase I
Award Amount:
$81,000.00
Agency:
HHS
Principal Investigator:
Serengulam Govindan
Abstract:
Our ultimate goal is to develop a readily usable rhenium-186-labeled monoclonal antibodyproduct for radioimmunotherapy of colorectal and other types of cancer. Rhenium-186 (t1/2=90h) hasbeta-emissions at 1.07 meV and 0.93 MeV, and imageable gamma-emission (9% abundance) at 137KeV. The Phase-I… More

Recombinant Bitistatin for Imaging Thrombi and Emboli

Award Year / Program / Phase:
1995 / SBIR / Phase I
Award Amount:
$95,563.00
Agency:
HHS
Principal Investigator:
Shui-On Leung
Abstract:
Bitistatin is a 84 amino acid peptide that recognizes the platelet glycoprotein IIb/IIIa receptor ademonstrated to target specifically to thrombi and emboli. The limited supply of bitistatin, as of tsnake venom of Bitis Arietans. The objective of this project is to produce bitistatin as a… More

CDR Grafted Antibody for Radioimmunotherapy of Lymphoma

Award Year / Program / Phase:
1995 / SBIR / Phase I
Award Amount:
$100,000.00
Agency:
HHS
Principal Investigator:
Gary Griffiths
Abstract:
N/a

CDR Grafted Antibody for Radioimmunotherapy of Lymphoma

Award Year / Program / Phase:
1996 / SBIR / Phase II
Award Amount:
$750,000.00
Agency:
HHS
Principal Investigator:
Gary Griffiths
Abstract:
This Phase I research will test the hypothesis that an optimum, commercially viable radioimmunotherY-90-radiolabeled cdr-grafted LL2 MAb, targeted against radiosensitive Non-Hodgkin's lymphoma. Y-90because of its desirable radiophysical properties, possible use on an out-patient basis and… More

TARGETED DRUG THERAPY OF PNEUMOCYSTIS CARINII INFECTION

Award Year / Program / Phase:
1996 / SBIR / Phase I
Award Amount:
$100,000.00
Agency:
HHS
Principal Investigator:
Abstract:
N/a

IMPROVED RADIOIODINATION METHODS FOR RADIOIMMUNOTHERAPY

Award Year / Program / Phase:
1997 / SBIR / Phase I
Award Amount:
$100,000.00
Agency:
HHS
Principal Investigator:
Govindan, serengulam v
Abstract:
N/a

IMAGING OF BREAST TUMOR RECEPTORS WITH TECHNETIUM-99M

Award Year / Program / Phase:
1997 / SBIR / Phase I
Award Amount:
$100,000.00
Agency:
HHS
Principal Investigator:
Mcbride, william j
Abstract:
N/a

IMPROVING TUMOR RADIOIMMUNOTHERAPY BY PNA PRETARGETING

Award Year / Program / Phase:
1998 / SBIR / Phase I
Award Amount:
$100,000.00
Agency:
HHS
Principal Investigator:
Karacay, Habibe
Abstract:
N/a

POSITRON EMISSION TOMOGRAPHY WITH MONOCLONAL ANTIBODIES

Award Year / Program / Phase:
1998 / SBIR / Phase I
Award Amount:
$100,000.00
Agency:
HHS
Principal Investigator:
Griffiths, Gary L
Abstract:
N/a

N/A

Award Year / Program / Phase:
1999 / SBIR / Phase II
Award Amount:
$750,000.00
Agency:
HHS
Principal Investigator:
Govindan serengulam v
Abstract:
N/a

TWO STEP TC99M IMAGING USING BISPECIFIC ANTIBODIES

Award Year / Program / Phase:
1999 / SBIR / Phase I
Award Amount:
$100,000.00
Agency:
HHS
Principal Investigator:
William J. Mcbride
Abstract:
Not Available We propose, in this Phase I program, to study the feasibility of a high-power terahertz source using narrow-line width, high-power, visible diode lasers in combination with an ultrafast photodetector/deipole antenna array. This method should produce milliwatts of tunable terahertz… More

BACTERIAL EXPRESSION OF LYMPHOMA RNRNASE IMMUNOTOXIN

Award Year / Program / Phase:
1999 / SBIR / Phase I
Award Amount:
$100,000.00
Agency:
HHS
Principal Investigator:
Shuion Leung
Abstract:
Not Available F&S proposes to develop high temperature multiplexed optical fiber sensors capable of simultaneous strain and temperature measurement using F&S' patented long period grating (LPG) technology. F&S will also investigate other optical fiber sensing approaches using patented extrinsic… More

PRE-TARGETED GALLIUM-68 POSITRON EMISSION TOMOGRAPHY

Award Year / Program / Phase:
1999 / SBIR / Phase I
Award Amount:
$100,000.00
Agency:
HHS
Principal Investigator:
Gary L. Griffiths
Abstract:
Not Available Current Band IV DIRCM laser sources suffer disadvantages such as excessive size and weight, limited duty cycle, low output power and the need for an operational warm up time. These disadvantages make it difficult to utilize these sources on space-limited combat aircraft.… More

N/A

Award Year / Program / Phase:
2000 / SBIR / Phase I
Award Amount:
$0.00
Agency:
HHS
Principal Investigator:
Hans J. Hansen
Abstract:
N/a

N/A

Award Year / Program / Phase:
2000 / SBIR / Phase II
Award Amount:
$442,937.00
Agency:
HHS
Principal Investigator:
Hans J. Hansen
Abstract:
N/a

Minimal-disease radioimmunotherapy of colorectal cancer

Award Year / Program / Phase:
2003 / SBIR / Phase I
Award Amount:
$100,000.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Colorectal cancer accounts for 15% of all cancers, and the 5-year survival rate for patients with metastatic tumors is close to zero. Targeted radiotherapy or radioimmunotherapy (RAIT) has the potential to bring about durable clinical responses in small-volume… More

Molecular Imaging by Affinity Enhancement PET

Award Year / Program / Phase:
2003 / SBIR / Phase I
Award Amount:
$119,171.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): The objective of this work is to develop a set of reagents that together comprise a new imaging system for detection of cancer, in its early, its metastatic, and its recurrent stages. Early detection, better treatment choices and new information that save… More

Tetravalent bispecific fusion antibody for immunotherapy

Award Year / Program / Phase:
2004 / SBIR / Phase I
Award Amount:
$134,285.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Immunotherapy based on a naked monoclonal antibody (mAb), such as rituximab, has emerged as a safe and effective modality for treatment of indolent and aggressive non-Hodgkin's lymphomas (NHL) and chronic lymphocytic leukemias (CLL). Almost half of the patients… More

F-18 FDG Peptides for Pretargeted PET Imaging of Pancrea

Award Year / Program / Phase:
2005 / SBIR / Phase I
Award Amount:
$134,285.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Our primary interest is to develop an imaging method based on bispecific antibody (bsMAb) pretargeting used in combination with F-18 labeled peptides. Such a method would improve the specificity for PET imaging based on the bsMAb's reactivity with either tumor… More

An Anti-CD-74 MAb-drug Conjugate for B-Cell Malignancies

Award Year / Program / Phase:
2005 / SBIR / Phase I
Award Amount:
$134,285.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): The objective of this work is to develop an antibody-drug conjugate that will be useful against B-cell malignancies that express the CD74 antigen. More specifically, the conjugate will be a doxorubicin derivative attached to the complementarity-determining… More

Dock and Lock: novel protein engineering

Award Year / Program / Phase:
2006 / SBIR / Phase I
Award Amount:
$134,285.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): The objective of this research is to develop a new generation of fusion proteins that can be used for improved imaging and therapy of cancer and other diseases by the method of pretargeting, which separates antibody localization from the delivery of diagnostic or… More

Novel RNase-based Immunotoxin for CD74-positive B-cell Malignancies

Award Year / Program / Phase:
2007 / SBIR / Phase I
Award Amount:
$134,285.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): This is an amended application of 1 R43 CA121468-01, which was originally submitted on July 29, 2005. Immunomedics, Inc. has developed a series of recombinant immunotoxins that are composed of two molecules of ranpirnas e (Rap), an amphibian ribonuclease (RNase),… More

MAb-based targeted chemotherapy of lung cancer

Award Year / Program / Phase:
2007 / SBIR / Phase I
Award Amount:
$114,334.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Lung cancer is one of the most common malignancies worldwide, and the 5-year survival rate is only 15%. Continued efforts with newer, more efficacious, therapies are warranted. Monoclonal-antibody (MAb)-directed cancer chemotherapy, using MAb-drug… More

Dock and Lock: Novel Protein Engineering

Award Year / Program / Phase:
2008 / SBIR / Phase II
Award Amount:
$887,626.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): The objective of this Phase II application is the commercial development of CEA-ImmunoPET for breast cancer imaging. CEA-ImmunoPET is a two-component product system comprising TF2, a trivalent, bispecific, anti-CEA x an ti-HSG constructs made by the Dock and Lock… More

MAb-based targeted chemotherapy of lung cancer

Award Year / Program / Phase:
2008 / SBIR / Phase II
Award Amount:
$964,355.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Lung cancer is one of the most common malignancies worldwide, and the 5-year survival rate is only 15%. As existing therapies do not significantly increase survival rate, there is an urgent need to develop newer therapi es that can augment the existing… More

An anti-CD74 MAb-drug conjugate for B-cell malignancies

Award Year / Program / Phase:
2008 / SBIR / Phase II
Award Amount:
$802,014.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): The goal of this work is to develop an antibody-doxorubicin conjugate for the targeted therapy of B-cell cancers that express the CD74 antigen. The Phase II project will focus on advancing this product for multiple myel oma, a common plasma cell malignancy that… More

F-18 Labeled Peptides for Pretargeted PET Imaging of Pancreatic Cancer

Award Year / Program / Phase:
2009 / SBIR / Phase II
Award Amount:
$1,122,961.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Our primary interest is to develop an imaging method based on bispecific antibody (bsMAb) pretargeting used in combination with F-18 labeled peptides. Such a method would improve the specificity for PET imaging based on the bsMAb's reactivity with either tumor… More

Combined radio- and immunotherapy of aggressive NHL

Award Year / Program / Phase:
2009 / SBIR / Phase I
Award Amount:
$859,792.00
Agency:
HHS
Principal Investigator:
William A. Wegener
Abstract:
DESCRIPTION (provided by applicant): The main goal of this Phase I/II SBIR application is to translate rapidly preclinical findings that show the advantage of using a combination radioimmunotherapy plus immunotherapy treatment regimen that uses non-com peting antibodies for the improved… More

Development of an interferon-alpha-veltuzumab conjugate for CD20-targeted therapy

Award Year / Program / Phase:
2009 / SBIR / Phase I
Award Amount:
$133,835.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Interferon-alpha-2 (IFNa2) is indicated for the therapy of a variety of hematopoietic and solid tumors. However, its therapeutic potential has not been fully realized primarily due to its short circulating half-life and systemic toxicity. Fusion of IFNa2 to a… More

Development of an interferon-alpha-veltuzumab conjugate for CD20-targeted therapy

Award Year / Program / Phase:
2010 / SBIR / Phase II
Award Amount:
$2,828,873.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): As a continuation of a successful Phase I SBIR, this Phase II application is directed towards the further development of a novel immunocytokine, named 20-2b, for improved therapy of B-cell lymphomas. In the United State s, there were 65,980 new cases of… More

Use of milatuzumab in modulating graft vs. host disease

Award Year / Program / Phase:
2011 / STTR / Phase I
Award Amount:
$191,143.00
Agency:
HHS
Principal Investigator:
Chien H. Chang – 973-605-1330
Research Institution:
CENTER FOR MOLECULAR MEDICINE AND IMMUNOLOGY.
RI Contact:
Abstract:
DESCRIPTION (provided by applicant): Control of GVHD by milatuzumab in hu-SCID mice Dendritic cells (DCs) are the primary initiator of graft-versus-host disease (GVHD), a major and life- threatening complication of allogeneic hematopoietic stem cell transplantation (alloHSCT). Depletion of DCs has… More

Bispecific antibody pretargeted immunoPET of prostate cancer

Award Year / Program / Phase:
2012 / SBIR / Phase I
Award Amount:
$276,833.00
Agency:
HHS
Principal Investigator:
William A. Wegener – 973-605-8200
Abstract:
DESCRIPTION (provided by applicant): This Phase I application is being submitted with the main objective to develop a highly sensitive and specific imaging method for prostate cancer that is based on a bispecific antibody (bsMAb) pretargeting procedure. The key features of this imaging system is the… More

Humanized Anti-Trop2-SN-38 Conjugate For Advanced Pancreatic Cancer

Award Year / Program / Phase:
2012 / SBIR / Phase I
Award Amount:
$227,025.00
Agency:
HHS
Principal Investigator:
William A. Wegener – 973-605-8200
Abstract:
DESCRIPTION (provided by applicant): The main objective of this Phase I SBIR application is to perform the first-in-man studies with a new antibody-drug conjugate (ADC) composed of a humanized antibody (hRS7) to the epithelial glycoprotein-1 antigen (EGP-1, also known as TROP-2) coupled to SN-38,… More

Novel Antithrombotic Diadenosine Tetraphosphate Analogs

Award Year / Program / Phase:
2013 / SBIR / Phase I
Award Amount:
$213,982.00
Agency:
HHS
Principal Investigator:
William A. Wegener – 973-605-8200
Abstract:
DESCRIPTION (provided by applicant): The overall goal of this SBIR application is to initiate a clinical trial with a bispecific antibody (bsMAb) pretargeting procedure for detecting pancreatic carcinoma, based on a highly specific antibody (PAM4) recognizing an epitope found in pancreatic mucin.… More

CBT Supervisor's Toolkit: Phase II

Award Year / Program / Phase:
2013 / SBIR / Phase I
Award Amount:
$200,782.00
Agency:
HHS
Principal Investigator:
Donglin Liu – 973-605-8200
Abstract:
DESCRIPTION (provided by applicant): Triple-negative breast cancer (TNBC) is a subset of breast cancers with poor prognosis and high mortality due to the lack of effective therapeutic regimens. This Phase I SBIR application is to develop E1-Rap, a novel immunoRNases, for treating TNBC. E1-Rap is a… More

Combined radio- and immunotherapy of aggressive NHL

Award Year / Program / Phase:
2013 / SBIR / Phase II
Award Amount:
$1,137,221.00
Agency:
HHS
Principal Investigator:
William A. Wegener – 973-605-8200
Abstract:
DESCRIPTION (provided by applicant): The main goal of this Phase I/II SBIR application is to translate rapidly preclinical findings that show the advantage of using a combination radioimmunotherapy plus immunotherapy treatment regimen that uses non-competing antibodies for the improved treatment… More